Impact of Direct Oral Anticoagulant Use on Endoscopic Presentation and In-Hospital Outcomes in Acute Upper Gastrointestinal Bleeding
In a retrospective multicenter study of 653 patients with acute upper gastrointestinal bleeding, direct oral anticoagulant use was associated with a higher frequency of gastric ulceration and lower frequency of esophageal varices but showed no statistically significant differences in in-hospital mortality, transfusion requirements, or other short-term outcomes compared to non-users.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
Every year, millions of people around the world take daily medication to keep their blood from clotting too easily. These drugs, known as direct oral anticoagulants, are a lifeline for those at risk of stroke or dangerous blood clots, allowing them to live fuller, safer lives. However, because these medicines thin the blood, they carry a known risk: if a person starts bleeding, it can be harder to stop. This is particularly true for bleeding in the upper part of the digestive system, such as the stomach or esophagus, which is a common medical emergency. When a patient arrives at the hospital with such a bleed, doctors must make rapid, high-stakes decisions. They need to know if the presence of these blood-thinning drugs changes the nature of the bleeding, makes it harder to treat, or leads to worse outcomes for the patient. For years, the medical community has watched closely to see if the type of medication a patient takes dictates the severity of the crisis they face.
A team of researchers from several hospitals across the United Kingdom set out to answer this question by looking at real-world data from a large group of patients. They focused on adults who arrived at the hospital with acute upper gastrointestinal bleeding and underwent an endoscopy, a procedure where a camera is passed down the throat to look inside the digestive tract. The team compared two groups of people: those who were taking direct oral anticoagulants at the time of their bleeding and those who were not. They examined the pictures taken during the endoscopy to see what caused the bleeding, the treatments doctors used to stop the bleeding, and what happened to the patients during their hospital stay, including whether they needed blood transfusions, intensive care, or if they survived the episode.
The study included 653 patients in total. Of these, 245 were taking the blood-thinning medication, while the remaining 408 were not. The researchers found that the two groups were very similar in age, with an average age of roughly 78 for those on the medication and 76 for those not on it. When they looked at the source of the bleeding, they noticed some interesting differences in the types of wounds found. Patients taking the medication were more likely to have bleeding from a gastric ulcer, a sore on the lining of the stomach, which appeared in about 12 percent of that group compared to just over 7 percent of the group not taking the drugs. Conversely, bleeding from esophageal varices, which are swollen veins in the food pipe often linked to liver disease, was less common in the medication group, appearing in only about 3 percent of patients compared to nearly 8 percent of those not taking the drugs. Despite these differences in where the bleeding started, the specific tools doctors used to stop the bleeding, such as clips, injections, or heat treatments, were used at very similar rates in both groups.
The most critical part of the study was looking at the final outcomes for the patients. The researchers wanted to know if being on the medication made the situation more dangerous. They found that the rates of death in the hospital were nearly identical: about 9 percent of the patients taking the medication died, compared to 10 percent of those who were not. Similarly, the need for blood transfusions was comparable, with roughly 17 percent of the medication group requiring a transfusion versus 14 percent of the other group. The number of patients who needed to be moved to an intensive care unit was also very low and similar for both sides, with less than 1 percent of the medication group and 2 percent of the non-medication group requiring such care. The average time spent in the hospital was also the same, at just over 11 days for everyone.
These findings suggest that for patients who arrive at the hospital with an acute upper gastrointestinal bleed, the fact that they are taking a direct oral anticoagulant does not automatically mean they will have a worse outcome than someone who is not. The study indicates that the presence of these drugs does not necessarily make the bleeding harder to control or the recovery more difficult in the short term. However, the researchers are careful to note that this conclusion comes from observing patterns in a specific group of patients and does not prove that the drugs have no effect at all. The data did not include detailed information on the specific type of drug, the dose, or the exact timing of the last dose, which are factors that could influence the severity of a bleed. Therefore, while the results are reassuring, they do not mean that doctors should ignore the medication when treating a patient. Instead, the study supports the idea that treatment decisions should be based on the individual patient's condition, the severity of the bleeding, and their overall health, rather than just the fact that they are taking a blood thinner. The work highlights that modern management of these emergencies can be effective for patients on these medications, but it also reminds us that every case remains unique and requires careful, personalized attention.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.